1 Small-Cap Stock to Research Further and 2 to Question
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here is one small-cap stock that could be the next 100 bagger and two that could be down big.
Market Cap: $133.4 million
With its technology found in common consumer electronics such as TVs and smartphones, Magnachip Semiconductor (NYSE:MX) is a provider of analog and mixed-signal semiconductors.
Why Do We Avoid MX?
Products and services are facing significant end-market challenges during this cycle as sales have declined by 18.5% annually over the last five years
Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable
Long-term business health is up for debate as its cash burn has increased over the last five years
Magnachip is trading at $3.70 per share, or 0.7x forward price-to-sales. If you're considering MX for your portfolio, see our FREE research report to learn more.
Market Cap: $1.77 billion
Gibraltar (NASDAQ:ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Does ROCK Worry Us?
Annual sales declines of 2.2% for the past two years show its products and services struggled to connect with the market during this cycle
Gross margin of 25.2% is below its competitors, leaving less money to invest in areas like marketing and R&D
Free cash flow margin dropped by 2 percentage points over the last five years, implying the company became more capital intensive as competition picked up
Gibraltar's stock price of $61 implies a valuation ratio of 12.4x forward P/E. Dive into our free research report to see why there are better opportunities than ROCK.
Market Cap: $739.1 million
Spun off from FTAI Aviation in 2021, FTAI Infrastructure (NASDAQ:FIP) invests in and operates infrastructure and related assets across the transportation and energy sectors.
Why Are We Positive On FIP?
Market share has increased this cycle as its 33.3% annual revenue growth over the last three years was exceptional
Exciting sales outlook for the upcoming 12 months calls for 78.2% growth, an acceleration from its two-year trend
At $6.43 per share, FTAI Infrastructure trades at 2.8x forward EV-to-EBITDA. Is now a good time to buy? Find out in our full research report, it's free.
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
AI Code Review Pioneer CodeRabbit Recognized in Redpoint's InfraRed 100
InfraRed Report Shows Cloud Infrastructure Powers Virtually All Software WALNUT CREEK, Calif., June 10, 2025--(BUSINESS WIRE)--CodeRabbit, the most advanced AI code review platform, today announced its inclusion on the Redpoint InfraRed 100. This prestigious list highlights the 100 up-and-coming private companies in Cloud Infrastructure, showcasing the future leaders set to revolutionize the market. CodeRabbit integrates foundational gen-AI models with multiple data sources that enhance the code context, leading to higher quality reviews, cutting down code review time and bugs in half. CodeRabbit's AI code reviews have been rapidly adopted by customers including The Linux Foundation, Groupon, Chegg, Trivago, and many more. Redpoint Ventures, a top-tier venture capital firm with a diverse portfolio including companies such as Snowflake, Twilio, Looker, Nextdoor, Ramp, Stripe, Nubank, HashiCorp, Netflix, Hims, and more, launched this list in 2023 to showcase the exceptional builders in the industry who are creating industry-transforming companies. To commemorate this achievement, CodeRabbit's co-founder and CEO Harjot Gill will join Redpoint at Nasdaq with other InfraRed 100 leaders to discuss the evolving landscape of cloud infrastructure. "We are honored to be recognized in the InfraRed 100, especially alongside such a distinguished group of cloud infrastructure companies. We founded CodeRabbit with the mission to transform code reviews with AI to help developers automate the tedious parts of software development. We believe that AI, when augmented with appropriate context and implemented with the right guardrails will identify defects that are hard to catch in manual reviews, leading to fewer bugs and faster release cycles," said Gill. "We thank the team at Redpoint for this recognition and congratulate all the companies on the list." For the complete list of companies included on this year's InfraRed 100 list and to read the full InfraRed industry report, click here. About CodeRabbit CodeRabbit is the pioneer of the AI code review category, evolving the historically manual and low-context review process into a more automated, context-aware workflow that's compatible with today's highly dynamic CI/CD pipeline. CodeRabbit enables engineering organizations that use code-gen agents to generate code at a fast pace to identify code quality issues before production, reducing code review cycles and allowing developers to reclaim valuable time. Headquartered in Walnut Creek, California, and funded by CRV, Flex Capital, and Engineering Capital, CodeRabbit is on a mission to transform code quality, security, and developer productivity with AI. Try CodeRabbit free at: About Redpoint Ventures: Redpoint has partnered with visionary founders to create new markets and redefine existing ones since 1999. We invest in startups across the seed, early and growth phases, and we're proud to have backed over 615 companies—including Snowflake, Looker, Kustomer, Twilio, 2U, DraftKings, Duo Security, HashiCorp, Stripe, Guild, HomeAway, Heroku, Netflix, and Sonos—with 183 IPOs and M+A exits. Redpoint manages $8.0 billion across multiple funds. For more information visit: View source version on Contacts Heather FitzsimmonsMindshare PR650-279-4360heather@
Business Wire
34 minutes ago
- Business Wire
VSTS Investors Have Opportunity to Lead Vestis Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vestis Corporation ('Vestis' or 'the Company') (NYSE: VSTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 2, 2024 and May 6, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 8, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Vestis misled investors about the actual extent of its ability to grow the business. The Company was not equipped to execute on planned strategic initiatives. The Company struggled to bring in new customers and retain existing customers. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Vestis, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
37 minutes ago
- Yahoo
2 Weight Loss Drug Stocks That Are Screaming Buys in June
Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool
